Hadlima Alternatives in Nebraska
Compare generic and therapeutic alternatives to Hadlima (adalimumab-bwwd (biosimilar)) available at Nebraska pharmacies. Save up to 82% on your prescription — no insurance required.
Top Alternatives in Nebraska
Hyrimoz (adalimumab biosimilar)
generic
High-concentration citrate-free Humira biosimilar
Avg cash price: $1100/mo
Humira (brand adalimumab)
brand
Original brand — same molecule at 5× the cost
Avg cash price: $6800/mo
Methotrexate
therapeutic
DMARD alternative — much cheaper, often combined with biologics
Avg cash price: $30/mo
Nebraska Prescription Assistance Programs
Nebraska Medicaid Rx
Prescription drug coverage for Nebraska Medicaid (Heritage Health) enrollees.
Eligibility: Low-income Nebraska adults, children, pregnant women, seniors, and people with disabilities. Nebraska expanded Medicaid in 2020.
Frequently Asked Questions
What is Hadlima and is it the same as Humira?
Hadlima (adalimumab-bwwd) is an FDA-approved biosimilar to Humira. It contains the same active molecule and is rated interchangeable in many states — meaning a pharmacist can substitute it for Humira without calling the doctor.
How much cheaper is Hadlima compared to Humira?
Hadlima typically costs 70–80% less than brand Humira. Brand Humira can exceed $6,000/month list price; biosimilars like Hadlima and Hyrimoz are often $1,000–$1,500/month.
Is Hadlima safe and effective?
FDA biosimilar approval requires demonstration of no clinically meaningful difference in safety or efficacy compared to the reference product (Humira). Millions of patients worldwide now use adalimumab biosimilars.
What is the difference between Hadlima and Hyrimoz?
Both are adalimumab biosimilars. Hadlima comes in standard and high-concentration (100 mg/mL) formulations. Hyrimoz is citrate-free (fewer injection site stinging). Both are FDA-interchangeable with Humira.
Can Script Unlock help access Hadlima?
Some Script Unlock pharmacies carry adalimumab biosimilars. Post your prescription — specialty pharmacies in the network may offer competitive pricing on Hadlima and other biosimilars.